

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Consultation on Batch 9 Health Technology Appraisal draft remits and scopes

Summary of comments and discussions at scoping workshops

Provisional title	Draft remit	Main points from consultation	Process MTA/ STA	Proposed changes to remit (in bold)	Costing implications of remit change
Buccal insulin for the management of type 1 diabetes 22 nd wave	To appraise the clinical and cost effectiveness of buccal insulin within its licensed indication for the management of type 1 diabetes.	Following the consultation exercise and the scoping workshop, the Institute is of the opinion that an appraisal of buccal insulin for the management of type 1 diabetes is appropriate. The Institute is of the opinion that the draft remit is appropriate.	STA	No changes proposed Given the anticipated date of the marketing authorisation and the expected referral date of this topic, issuing timely guidance for this technology will be possible.	No change in cost impact anticipated.
Apixaban for the prevention of venous thromboembolism in people undergoing elective knee and hip replacement surgery 21 st wave	To appraise the clinical and cost effectiveness of apixaban, within its licensed indication, for the prevention of venous thromboembolism in people undergoing elective knee and hip replacement surgery.	Following the consultation exercise and the scoping workshop, the Institute is of the opinion that an appraisal of apixaban for the prevention of venous thromboembolism in people undergoing elective knee and hip surgery is appropriate. The Institute is of the opinion that the draft remit is appropriate.	STA	No changes proposed Given the anticipated date of the marketing authorisation and the expected referral date of this topic, issuing timely guidance for this technology will be possible.	No change in cost impact anticipated.

<p>Apixaban for the of prevention venous thromboembolism in acute medical illness</p> <p>21st wave</p>	<p>To appraise the clinical and cost effectiveness of apixaban, within its licensed indication, for the prevention of venous thromboembolism in acute medical illness.</p>	<p>Following the consultation exercise and the scoping workshop, the Institute is of the opinion that an appraisal of apixaban for the prevention of venous thromboembolism in people with acute medical illness is appropriate.</p> <p>The Institute is of the opinion that the draft remit is appropriate.</p>	<p>STA</p>	<p>No changes proposed</p> <p>Given the anticipated date of the marketing authorisation and the expected referral date of this topic, issuing timely guidance for this technology will be possible.</p>	<p>No change in cost impact anticipated.</p>
<p>Aripiprazole for the treatment and prevention of acute manic and mixed episodes in bipolar disorder in children and adolescents</p> <p>22nd wave</p>	<p>To appraise the clinical and cost effectiveness of aripiprazole, within its licensed indication, for the treatment and prevention of acute manic and mixed episodes in bipolar disorder in children and adolescents.</p>	<p>Following the consultation exercise and the scoping workshop, the Institute is of the opinion that an appraisal of aripiprazole for the prevention of acute manic and mixed episodes in bipolar disorder in children and adolescents is appropriate.</p> <p>The Institute is of the opinion that the draft remit is appropriate.</p>	<p>STA</p>	<p>No changes proposed</p> <p>Given the anticipated date of the marketing authorisation and the expected referral date of this topic, issuing timely guidance for this technology will be possible.</p>	<p>No change in cost impact anticipated.</p>